ZYBERNO
Stock Report
Updated Aug 22, 2026

APTOSE BIOSCIENCES INC. (APTOF)

Healthcare • OTC

$1.69

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
APTOSE BIOSCIENCES INC. (APTOF) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (0.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

APTOSE BIOSCIENCES INC. (APTOF) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, APTOF generated -$36.23M in Owner Earnings. Capital was deployed as follows: $53.00K invested in capital expenditures.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.69
Market Cap:$4.31M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$486.61K
Ev Ebitda Ratio:23.17x

Price Action & Momentum (3)

Momentum Percentile:90 / 100
% of 52-Week High:91.4%
B. Profitability Assessment

Return Metrics (1)

ROA:-337.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$638.46
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:7.2%
Latest Earnings Filed:2026-05-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.55x
Quick Ratio:0.55x
Cash Ratio:0.36x

Leverage Analysis (1)

Debt To Ebitda:13.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-5,084,000.00
Cash And Cash Equivalents:4,100,000.00
Long Term Debt:$193.00K
Net Debt:-$3.83M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00$0.00

Bottom Line Performance (3)

-$27.56M
Income Before Tax:-$20.90M
Ebitda Ttm:21,000.00

Operating Expenses (5)

Operating Expenses:26,444,000.00
R And D Expense:12,598,000.00
Sga Expense:13,846,000.00
Income Tax Expense:$0.00
Interest Expense:-212,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$10.72M
Current Assets:$6.16M
Ppe Net:2,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:45,395,000.00
Current Liabilities:11,239,000.00
Long Term Debt:$193.00K
Short Term Debt:$80.00K

Equity & Capital (3)

Equity:-$34.67M
Retained Earnings:-$574.07M
Common Stock:459,771,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,810,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:129,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$25.04M-$25.09M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:53,000.00

Financing Activities (3)

Financing Cash Flow:$5.85M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:21,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-10.79
-$10.79
Earnings Per Share Ttm:-$10.80

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$8.62

Book Value & Capital (2)

Book Value Per Share:-$13.58
Cash Per Share:1.61

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:10.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$36.23M
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:APTOF
Company Name:APTOSE BIOSCIENCES INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:OTC
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:2.55M
Shares Outstanding Basic:2.55M
Shares Outstanding Diluted:2.55M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-22 07:40:21 UTC
Data Timestamp:2026-08-22T07:40:21.941527
Scroll to Top